Incidence of Drug Interactions Identified by Clinical Pharmacists in Veterans Initiating Treatment for Chronic Hepatitis C Infection.

Andreina A OttmanMary L TownsendMohamed G HashemVincent P DiMondiRachel B Britt

Published in: The Annals of pharmacotherapy (2018)

This study suggests that DDIs are prevalent among patients treated with DAAs for HCV. A HCV clinical pharmacist can help optimize patient care by identifying DDIs and recommending interventions to providers.

Keyphrases

hepatitis c virus
risk factors
human immunodeficiency virus
primary care
hiv infected
combination therapy
antiretroviral therapy